Genetic testing company Natera (NASDAQ: NTRA). will be reporting earnings this Thursday after the bell. Here’s what to expect.
Natera beat analysts’ revenue expectations by 14.7% last quarter, reporting revenues of $546.6 million, up 32.2% year on year. It was a very strong quarter for the company, with an impressive beat of analysts’ revenue estimates and full-year revenue guidance exceeding analysts’ expectations.
Is Natera a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Natera’s revenue to grow 17% year on year to $514.4 million, slowing from the 63.9% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.35 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Natera has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 13.6% on average.
Looking at Natera’s peers in the immuno-oncology segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Incyte delivered year-on-year revenue growth of 20%, beating analysts’ expectations by 8.5%, and Regeneron reported flat revenue, topping estimates by 5.1%. Incyte traded down 3.2% following the results while Regeneron was up 11.7%.
Read our full analysis of Incyte’s results here and Regeneron’s results here.
Investors in the immuno-oncology segment have had steady hands going into earnings, with share prices flat over the last month. Natera is up 14.7% during the same time and is heading into earnings with an average analyst price target of $202.50 (compared to the current share price of $195.50).
The biggest winners—Microsoft, Alphabet, Coca-Cola, Monster Beverage—were all riding powerful megatrends before Wall Street caught on. We’ve just identified an under-the-radar profitable growth stock positioned at the center of the AI boom. Get it FREE here before the crowd discovers it. GO HERE NOW.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
